Statistical documentation for multi-disease, multi-domain platform trials: our experience with the Staphylococcus aureus Network Adaptive Platform trial
Publication date
2025-02-11
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Platform trials have become widely adopted across multiple disease areas over recent years, however, guidelines for operationalising these trials have not kept pace. We outline a series of documents that summarise the statistical components, and implicit processes, of the Staphylococcus aureus Network Adaptive Platform (SNAP) trial to provide an informal template for other researchers and reviewers of platform trials. We briefly summarise the content and role of the core protocol, statistical appendix, domain-specific appendices, simulation report, statistical implementation guides, data safety and monitoring committee (DSMC) reports, and domain-specific statistical analysis plans and final reports, and a transparent governance structure that ensures separate blinded and unblinded statistical teams. In the absence of guidelines or checklists for platform trial statistical documents, we hope to provide useful guidance to others in terms of what has worked so far for the SNAP trial, stimulate discussion, and inform a future consensus.Trial registration NCT05137119 . Registered on 30 November 2021.
Keywords
Data Interpretation, Statistical, Documentation, Humans, Research Design, Staphylococcal Infections/microbiology, Staphylococcus aureus, Treatment Outcome, Journal Article, Letter
Citation
Mahar, R K, McGlothlin, A, Dymock, M, Barina, L, Bonten, M, Bowen, A, Cheng, M P, Daneman, N, Goodman, A L, Lee, T C, Lewis, R J, Lumley, T, McLean, A R D, McQuilten, Z, Mora, J, Paterson, D L, Price, D J, Roberts, J, Snelling, T, Tverring, J, Webb, S A, Yahav, D, Davis, J S, Tong, S Y C, Marsh, J A & SNAP Global Trial Steering Committee 2025, 'Statistical documentation for multi-disease, multi-domain platform trials : our experience with the Staphylococcus aureus Network Adaptive Platform trial', Trials, vol. 26, no. 1, 49. https://doi.org/10.1186/s13063-024-08684-8